Mode of action analysis for mouse liver tumor formation by MGK-264 and human relevance

2025/11/27

Pub Med URL https://pubmed.ncbi.nlm.nih.gov/40846131/

Yano, J. Kawamoto, K. Shimotsuma, Y. Ogata, K. Matsunaga, K. Abe, J. Fukunaga, S. Osimitz, T. G. Lake, B. G. Asano, H.
Regul Toxicol Pharmacol. 2025 Dec;163:105929. doi: 10.1016/j.yrtph.2025.105929.

VIEW AS PDF

RXR agonist S169 inhibits HBV/HDV entry in vitro by disrupting KIF4-dependent NTCP trafficking

2025/11/27

Pub Med URL https://pubmed.ncbi.nlm.nih.gov/40523562/

Gad, S. A. Abo Elwafa, D. A. Hussein, S. A. Fukano, K. Kato, T. Shoji, I. Chayama, K. Muramatsu, M. Isogawa, M. Wakita, T. Merk, D. Aly, H. H.
Antiviral Res. 2025 Aug;240:106214. doi: 10.1016/j.antiviral.2025.106214.

VIEW AS PDF

A novel synthetic bile acid derivative inhibits hepatitis B virus infection at entry step by interfering with the oligomerization of sodium taurocholate co-transporting polypeptide

2025/11/27

Pub Med URL https://pubmed.ncbi.nlm.nih.gov/40889532/

Rsi Suwardana, G. N. Abe, T. Deng, L. Matsui, C. Okitsu, T. Yamada, T. Hatano, M. Wiriyasermkul, P. Nagamori, S. Gad, S. A. Aly, H. H. Nishitsuji, H. Shimotohno, K. Shoji, I.
Antiviral Res. 2025 Aug 30;243:106267. doi: 10.1016/j.antiviral.2025.106267.

VIEW AS PDF

Potential for Core Fucose-Targeted Therapy Against HBV Infection of Human Normal Hepatocytes

2025/11/27

Pub Med URL https://pubmed.ncbi.nlm.nih.gov/41012670/

Takamatsu, S. Morita, C. Sakon, D. Nakamura, K. Hishii, H. Kondo, J. Ueda, K. Miyoshi, E.
Viruses. 2025 Sep 15;17(9):1242. doi: 10.3390/v17091242.

VIEW AS PDF

Species-specific gene expression manipulation in humanized livers of chimeric mice via siRNA-encapsulated lipid nanoparticle treatment

2025/11/27

Pub Med URL https://www.ncbi.nlm.nih.gov/pubmed/40927764

Yamazaki, K. Kubara, K. Sugahara, G. Muto, H. Yamamoto, M. Mano, Y. Mitsuhashi, K. Yamasaki, C. Ishida, Y. Tateno, C. Suzuki, Y.
Mol Ther Methods Clin Dev. 2025 Apr 14;33(2):101466. doi: 10.1016/j.omtm.2025.101466.

VIEW AS PDF

Prediction of human pharmacokinetics of procymidone and its major phase I and II metabolites using a PBPK__ model with enterohepatic circulation

2025/09/17

Pub Med URL https://pubmed.ncbi.nlm.nih.gov/40840616/

Hirasawa, K. Adachi, T. Takeuchi, H. Kuroda, T. Abe, J. Nakajima, M.
Toxicol Appl Pharmacol. 2025 Aug 19;504:117525. doi: 10.1016/j.taap.2025.117525.

VIEW AS PDF

Modeling of hepatitis B virus infection spread in primary human hepatocytes

2025/09/17

Pub Med URL https://pubmed.ncbi.nlm.nih.gov/40757857/

Shi, Z. Tsuge, M. Collier, N. Takeuchi, Y. Uchida, T. Rutter, C. M. Teraoka, Y. Uprichard, S. L. Ishida, Y. Tateno, C. Ozik, J. Dahari, H. Chayama, K.
J Virol. 2025 Aug 4:e0092725. doi: 10.1128/jvi.00927-25.

VIEW AS PDF

Assessing hepatitis B virus infectivity in blood components following pathogen reduction using a human hepatocyte model

2025/09/17

Pub Med URL https://pubmed.ncbi.nlm.nih.gov/40708291/

Visser, B. J. Biswas, S. Eltahan, R. Fares-Gusmao, R. Yegneswaran, S. Mufti, N. Villa, C. H. McGivern, D. R.
Transfusion. 2025 Jul 24. doi: 10.1111/trf.18357.

VIEW AS PDF

miRNA-29b-1-5p mediates an antiviral activity by targeting the HBV entry receptor in human hepatocytes

2025/09/17

Pub Med URL https://www.nature.com/articles/s41598-025-09655-y

Gailhouste, L. Furutani, Y. Qin, X. Y. Higuchi, S. Toguchi, M. Yanaka, K. Watashi, K. Wakita, T. Kojima, S.
Sci Rep. 2025 Jul 3;15(1):23725. doi: 10.1038/s41598-025-09655-y.

VIEW AS PDF

Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection

2025/09/17

Pub Med URL https://www.ncbi.nlm.nih.gov/pubmed/40486136

Zhou, J. Kaiser, H. Rocha, E. Terrell, A. N. Corti, D. Purcell, L. A. Lempp, F. A. Puschnik, A. S.
JHEP Rep. 2025 Mar 22;7(6):101400. doi: 10.1016/j.jhepr.2025.101400. eCollection

VIEW AS PDF

An evaluation of the human relevance of the hepatocellular tumors observed in mice treated with synthetic fungicide, pyridachlometyl, based on mode of action

2025/09/17

Pub Med URL https://www.ncbi.nlm.nih.gov/pubmed/40488882

Kawamoto, K.Shimotsuma, Y.Maeda, K. Matsunaga, K. Asano, H. Cohen, S. M. Yamada, T.
Arch Toxicol. 2025 Jun 9. doi: 10.1007/s00204-025-04099-9.

VIEW AS PDF

Quantitative Prediction of Drug-Drug Interactions Arising from CYP3A4 Induction using Chimeric Mice with Humanized Liver

2025/09/17

Pub Med URL https://pubmed.ncbi.nlm.nih.gov/40498703/

Nakayama, K. Negoro, T. Takubo, H. Hayashi, A. Taniguchi, T. Nomura, Y. Iwanaga, K.
Xenobiotica. 2025 Jun 11:1-19. doi: 10.1080/00498254.2025.2518239.

VIEW AS PDF

Clinical potential of SAG-524: A novel HBV RNA destabilizer with a unique mechanism of action

2025/09/17

Pub Med URL https://www.ncbi.nlm.nih.gov/pubmed/40026852

Tanaka, Yasuhito
Glob Health Med. 2025 Feb 28;7(1):64-66. doi: 10.35772/ghm.2024.01078.

VIEW AS PDF

Application of humanized mice to toxicology studies: properties of chimeric mice with humanized liver (PXB-mice) for hepatotoxicity

2025/09/17

Pub Med URL https://pubmed.ncbi.nlm.nih.gov/40190627/

Sultana, N. Izawa, T. Kamei, T. Fujiwara, S. Ito, Y. Takami, Y. Kuwamura, M.
Drug Metab Dispos. 2025 Feb;53(2):100025. doi: 10.1016/j.dmd.2024.100025.

VIEW AS PDF

Identification of glycogen synthase kinase 3alpha/beta as a host factor required for HBV transcription using high-throughput screening

2025/05/08

Pub Med URL https://pubmed.ncbi.nlm.nih.gov/39847392/

Nishitsuji, H. Naito, Y. Murakami, Y. Sugiyama, M. Mizokami, M. Shoji, I. Murata, T. Shimotohno, K.
Hepatology. 2025 Jan 23. doi: 10.1097/HEP.0000000000001239.

VIEW AS PDF

Identification of novel antiviral host factors by functional gene expression analysis using in vitro HBV infection assay systems

2025/05/08

Pub Med URL https://www.ncbi.nlm.nih.gov/pubmed/40048440

Nosaka, T. Naito, T. Akazawa, Y. Takahashi, K. Matsuda, H. Ohtani, M. Nishizawa, T. Okamoto, H. Nakamoto, Y.
PLoS One. 2025 Mar 6;20(3):e0314581. doi: 10.1371/journal.pone.0314581.

VIEW AS PDF

Quantitative prediction of drug disposition for uridine diphosphate-glucuronosyltransferase substrates using humanized mice

2025/05/08

Pub Med URL https://www.ncbi.nlm.nih.gov/pubmed/40054035

Miyake, T. Fujita, Y. Hirabayashi, M. Komiyama, N. Morita, K. Tachibana, T. Terao, K.
Drug Metab Dispos. 2025 Feb 10;53(4):100050. doi: 10.1016/j.dmd.2025.100050.

VIEW AS PDF

Development of human growth hormone-treated chimeric mice with humanized livers for an evaluation model of drug-induced fatty liver disease

2025/05/08

Pub Med URL https://www.ncbi.nlm.nih.gov/pubmed/39979474

Morioka, S. Sanoh, S. Ishida, Y. Furukawa, S. Ogawa, Y.Kotake, Y. Tateno, C.
Arch Toxicol. 2025 Feb 21. doi: 10.1007/s00204-025-03986-5.

VIEW AS PDF

Investigation of Biotransformation Pathways in a Chimeric Mouse with a Humanized Liver

2025/05/08

Pub Med URL https://pubmed.ncbi.nlm.nih.gov/39940909/

Karlsson, I. B. Ekdahl, A. Etchingham-Coll, H. Li, X. Q. Ericsson, C. Ahlqvist, M. Samuelsson, K.
Int J Mol Sci. 2025 Jan 28;26(3):1141. doi: 10.3390/ijms26031141

VIEW AS PDF

Endothelial lipase-binding peptides similar to netrin-1 inhibit hepatitis B virus infection

2025/05/08

Pub Med URL https://www.ncbi.nlm.nih.gov/pubmed/39865491

Ide, M. Tabata, N. Murai, K. Yonemura, Y. Wang, Y. Ishida, A. Shirasaki, T. Kaneko, S. Ito, S. Honda, M. Yanagawa, H.
FEBS Lett. 2025 Jan 25. doi: 10.1002/1873-3468.15101.

VIEW AS PDF